MDNAF
Price
$0.97
Change
-$0.03 (-3.00%)
Updated
Nov 13 closing price
Capitalization
81.56M
Earnings call today
Intraday BUY SELL Signals
VIR
Price
$5.47
Change
-$0.24 (-4.20%)
Updated
Nov 13 closing price
Capitalization
761.01M
97 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MDNAF vs VIR

Header iconMDNAF vs VIR Comparison
Open Charts MDNAF vs VIRBanner chart's image
Medicenna Therapeutics
Price$0.97
Change-$0.03 (-3.00%)
Volume$22.71K
Capitalization81.56M
Vir Biotechnology
Price$5.47
Change-$0.24 (-4.20%)
Volume$1.13M
Capitalization761.01M
MDNAF vs VIR Comparison Chart in %
View a ticker or compare two or three
VS
MDNAF vs. VIR commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDNAF is a Hold and VIR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (MDNAF: $0.97 vs. VIR: $5.47)
Brand notoriety: MDNAF and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDNAF: 29% vs. VIR: 83%
Market capitalization -- MDNAF: $81.56M vs. VIR: $761.01M
MDNAF [@Biotechnology] is valued at $81.56M. VIR’s [@Biotechnology] market capitalization is $761.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDNAF’s FA Score shows that 0 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).

  • MDNAF’s FA Score: 0 green, 5 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, VIR is a better buy in the long-term than MDNAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDNAF’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).

  • MDNAF’s TA Score: 5 bullish, 6 bearish.
  • VIR’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, MDNAF is a better buy in the short-term than VIR.

Price Growth

MDNAF (@Biotechnology) experienced а -8.49% price change this week, while VIR (@Biotechnology) price change was +6.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

MDNAF is expected to report earnings on Nov 14, 2025.

VIR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VIR($761M) has a higher market cap than MDNAF($81.6M). MDNAF YTD gains are higher at: -12.838 vs. VIR (-22.207). MDNAF has higher annual earnings (EBITDA): -21.81M vs. VIR (-586.27M). VIR has more cash in the bank: 606M vs. MDNAF (20.5M). MDNAF has less debt than VIR: MDNAF (162K) vs VIR (102M). VIR has higher revenues than MDNAF: VIR (14.4M) vs MDNAF (0).
MDNAFVIRMDNAF / VIR
Capitalization81.6M761M11%
EBITDA-21.81M-586.27M4%
Gain YTD-12.838-22.20758%
P/E RatioN/AN/A-
Revenue014.4M-
Total Cash20.5M606M3%
Total Debt162K102M0%
FUNDAMENTALS RATINGS
MDNAF vs VIR: Fundamental Ratings
MDNAF
VIR
OUTLOOK RATING
1..100
6412
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3851
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDNAF's Valuation (46) in the null industry is in the same range as VIR (50). This means that MDNAF’s stock grew similarly to VIR’s over the last 12 months.

MDNAF's Profit vs Risk Rating (100) in the null industry is in the same range as VIR (100). This means that MDNAF’s stock grew similarly to VIR’s over the last 12 months.

VIR's SMR Rating (97) in the null industry is in the same range as MDNAF (98). This means that VIR’s stock grew similarly to MDNAF’s over the last 12 months.

MDNAF's Price Growth Rating (38) in the null industry is in the same range as VIR (51). This means that MDNAF’s stock grew similarly to VIR’s over the last 12 months.

VIR's P/E Growth Rating (23) in the null industry is significantly better than the same rating for MDNAF (100). This means that VIR’s stock grew significantly faster than MDNAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDNAFVIR
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
66%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 22 days ago
82%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 11 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
70%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
MDNAF
Daily Signal:
Gain/Loss:
VIR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HSNGF16.67N/A
N/A
Hang Seng Bank Ltd.
FSEN13.49N/A
N/A
FS Energy & Power Fund
NMBF16.05N/A
N/A
NMB Finl. Corp
MBCOF0.13N/A
N/A
MARVEL BIOSCIENCES CORP.
IVCGF21.21-0.14
-0.64%
IVECO GROUP NV

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-2.40%
LRMR - MDNAF
25%
Poorly correlated
-7.16%
VIR - MDNAF
25%
Poorly correlated
N/A
STOK - MDNAF
23%
Poorly correlated
+0.08%
CGEM - MDNAF
23%
Poorly correlated
+7.05%
PTCT - MDNAF
22%
Poorly correlated
+1.53%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with SANA. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
N/A
SANA - VIR
65%
Loosely correlated
-4.25%
CPRX - VIR
48%
Loosely correlated
-1.39%
AXON - VIR
47%
Loosely correlated
-0.47%
NRIX - VIR
45%
Loosely correlated
-5.37%
RLAY - VIR
44%
Loosely correlated
-1.91%
More